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Background: BCL-2 family proteins BAK and BAX orchestrate outer mitochondrial membrane permeabilization
(MOMP) during apoptosis by forming pores in the membrane to release apoptogenic factors that commits a cell to
death. BAK and BAX therefore function as a ‘point of no return’ in the apoptotic cascade. BAK activation is a multi-
step process involving conformational changes, mediated by BH3-only proteins or p53, which lead eventually to
oligomerization and pore formation. Further, recent reports show that BAK activation is also linked to and
dependent upon dephosphorylation of both tyrosine and serine residues.
Findings: We hypothesized that phosphorylation of BAK at tyrosine residue 110 (Y110) was functionally important
during the BAK activation process. BAK/BAX double knockout HCT116 cells expressing a phosphor-mimetic BAK
mutant (BAK Y110E), showed impaired dimerization and multimerization capacity when treated with either UV
irradiation or etoposide when compared to cells reconstituted to express wild-type BAK. The Y110E mutant also
showed decreased release of cytochrome c from isolated mitochondria challenged with tBid protein, resulting in a
failure to activate caspase 3. Interestingly, co-immunoprecipitation experiments suggest that a negative charge at
this residue may be important for the recruitment of Bid to BAK, but conversely that this also impairs BAK:BAK
interactions.
Conclusion: These findings implicate dephosphorylation of Y110 as having an important mechanistic role in BAK
activation, and underscores how post-translational modifications are intimately linked and coupled to the protein-
protein interactions required for BAK activation during apoptosis.
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The abrogation of apoptotic responses is a common fea-
ture of almost all cancer cells. Whether or not a cell
undergoes apoptosis in response to stress depends on
responses following the receipt of signals generated by
cellular damage. The mitochondrial apoptotic pathway is
regulated by BCL-2 proteins that can be divided into
different pro- and anti-apoptotic groups depending on
their structure and function [1]. Pro-apoptotic BH3-only
proteins, such as Bid, Bim and Noxa, are required for
the activation of multi-domain BCL-2 effector proteins
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distribution, and reproduction in any mediumgateway for mitochondrial apoptosis to proceed, indeed
cells lacking both BAK and BAX fail to undergo mito-
chondrial apoptosis [2]. The BAK responds to a myriad of
death signals and plays a key role in executing mitochon-
drial apoptosis, effecting MOMP through oligomerization
of the protein that releases apoptogenic factors including
cytochrome c, that in turn lead to downstream activation
of caspase 3. BAK activation is complex, involving a num-
ber of intra-molecular conformational changes leading to
dimerization followed by oligomerization [2-4]. An early
event during BAK activation is a conformational change
towards to N-terminus of the protein [5]. This is followed
by exposure of the BAK BH3 domain that then inserts
into a hydrophobic groove on another BAK molecule
leading to dimer formation [6]. Resultant homodimers
then can form higher order structures via interactiontral Ltd. This is an Open Access article distributed under the terms of the
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ational change can be brought about by one of two mech-
anisms: first, by the transient binding of BH3-only
proteins (such as tBid) [8] to the BAK hydrophobic groove
[2,9], or alternatively by the binding of p53 to residues
near the BAK N-terminus [10-12]. Binding of BH3 pro-
teins such as tBid to the BAK hydrophobic groove occurs
with high affinity, but is necessarily transient as this same
region of BAK is also required to nucleate BAK
multimerization. Recently a model of BAK activation that
tries to take into account the differing affinities of BH3
proteins for both pro- and anti-apoptotic BCL-2 proteins
has been proposed [13].
In healthy, otherwise undamaged cells, BAK is present
almost exclusively in a very heavily phosphorylated form.
We recently demonstrated that BAK activation for apop-
tosis induction is closely linked to, and indeed dependent
upon, specific dephosphorylation events on the protein
[14]. The initial event in the BAK activation process is de-
phosphorylation at tyrosine 108 (Y108), an obligatory step
that is required to permit conformational change by BH3
or p53 proteins [14,15]. Further, we found that a subse-
quent PP2A-mediated dephosphorylation of BAK at serine
117 (S117) was required both for BH3 proteins to gain
access to the BAK hydrophobic groove, and permit BAK
dimerization via BAK-BH3:BAK-groove interactions [16].
During our investigations into the role of phosphoryl-
ation in regulating BAK activation, we reported in mass
spectrometry analysis that BAK was also phosphorylated
at residue Y110 [14]. Mutation of this residue to mimic
either the dephosphorylated or phosphorylated forms of
the protein (BAK mutants Y110F and Y110E respectively)
did not affect the ability of BAK to undergo N-terminal
conformational change [14]. However, modelling using
PyMol based on BAK structure 2IMS, suggested that
phosphorylation at Y110 might impinge upon the ability
of BH3 proteins to bind BAK and may also inhibit BAK
multimerization, as the Y110 side chain, like that of S117,
may occlude access to the hydrophobic groove (Figure 1A).
To test this idea, we performed multimerization assays
using sub-cellular fractions enriched in mitochondria from
HCT116bak−/−bax−/− cells that had been reconstituted to
express either wild-type (WT) or mutant BAK proteins
(HCT-BAK cells). Cross-linking reactions were performed
with the sulfhydryl-to-sulfhydryl crosslinker BMH (1, 6-
bismaleimidohexane, Pierce) on sub-cellular fractions
enriched in mitochondria, then analysed by western blot-
ting to detected BAK multimers, as previously described
[14,16]. Following DNA damage by UV, BAK dimers,
trimers and higher-order complexes were observed with
WT BAK and the Y110F mutant, but multimer formation
was impaired severely by the Y110E mutation (Figure 1B,
upper panel). As we have noted previously, BAK cross-
linking with BMH can be problematic with the formationof a faster migrating intra-molecularly cross-linked mono-
meric BAK protein (Mx) and generation of non-specific
dimer bands without any DNA damage. A further cross-
linking experiment a different sulfhydryl crosslinker,
BMOE (Bismaleimidoethane), that generates only BAK
dimers and at the same time minimizes the detection of
both intra-molecularly cross-linked BAK monomers and
non-specific dimer forms [16], supported the previous
experiments with dimers being detected only when WT
or the Y110F mutant was used (Figure 1B, lower panel).
When the experiment was repeated using etoposide as the
apoptotic inducer in place of UV, again dimers were read-
ily detected in cells expressing the WT and Y110F pro-
teins, but were not generated by the Y110E mutant
(Figure 1C). The stronger dimer band present generated
by the Y110F mutant compared to WT we suppose may
be due to the mutant forming dimers more readily if the
WT protein was not fully dephosphorylated following UV
damage.
The failure of the BAK Y110E mutant to dimerize or
multimerize we reasoned may be due to interference
with the binding of BH3 proteins, as observed previously
for the S117E phosphor-mimic [16]. We therefore tested
the ability of the BH3-activator protein tBid to release
cytochrome c from mitochondrial preparations using a
previously established method [16,17]. When purified
tBid protein was incubated with mitochondrial prepara-
tions from cells expressing either the WT or Y110F BAK
proteins, cytochrome c was readily released into the super-
natant (Figure 2A). Consistent with the multimerization
assays, tBid was unable to release cytochrome c from
mitochondrial preparations from the BAK-Y110E mu-
tant cells compared to the HCT116-BAK or HCT116-
BAKY110F cells (Figure 2A). The small quantity of
cytochrome c that was detected in the supernatant
fraction derived from the Y110E mutant might be due
to the mutant being very inefficient at releasing cyto-
chrome c since the substituted amino acid may not
correctly mimic a phosphor-tyrosine residue, however
we have noted that processing of the samples leads to
a degree of leakiness of the mitochondrial preparations
where mitochondria expressing BAK mutants we find
to be more fragile compared to cells expressing WT
BAK, as previously noted [16]. Likewise, the Y110F
mutant showed amounts of cytochrome c retained in
the pellet fraction decreased somewhat when mito-
chondrial preparations were treated with increasing
amounts of tBid, but by comparison cytochrome c was
readily detected in the supernatant fraction even in the
absence of tBid, and did not increase to the same extent
as observed for the WT BAK protein. To investigate
further whether the cytochrome c release was likely to be
functionally significant and bypass potential problems of
mitochondrial fragility, we performed caspase 3 activation
Figure 1 Effects of mutation of tyrosine 110 (Y110) on the
ability of BAK to form multimers following DNA damage. (A)
PyMol generated model of BAK structure using PBD file 2IMS.
Locations on the α4 helix of Y108 (red), together with S117 (blue)
and Y110 (red) where the side chains of these residues face the
hydrophobic surface groove (green), are indicated. Both the BH3
domain and BH1 encompassing α2-α5 helices (residue 70–145)
constitutes the hydrophobic surface groove. (B) BAK multimerization
following DNA damage was analysed in HCT116-BAK cells as
described in [16]. HCT116 DKO cells were reconstituted with the WT
BAK, Y110F or Y110E BAK proteins. Mitochondria were isolated from
cells expressing WT, Y110F and Y110E in ±UV 10mJ/cm2 for 8 hrs.
100 μg of mitochondria were cross-linked with either BMH (top
panel) or BMOE (bottom panel). BAK was detected by western blot
using a rabbit anti BAK monoclonal (abcam, Y164). The input was
the 5% of mitochondrial extract used in the cross-linking studies to
ensure equal loading (middle panel). Non cross-linked BAK runs as a
monomer (M) and also as an intra-molecularly linked monomer (Mx).
BAK dimers (D) and trimers (T) and higher order structures are
indicated. Image is representative of 3 independent experiments.
(C) Similar multimerization experiment to (B) was performed with
HCT116 cells expressing WT BAK, Y110F or Y110E proteins ± 50 μM
etoposide treatment for 8 hrs. Mitochondrial proteins were cross-
linked with BMOE as described previously and detected as above.
Note that BMOE generates only dimer forms of BAK.
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only activated caspase 3 using FACS on intact cells. This
revealed that UV irradiation resulted in an increase in
caspase 3 activation in BAK WT or Y110F cells, but
in marked contrast no caspase 3 activation was
detected in UV-irradiated Y110E cells, findings
in-line with and supporting the cytochrome c release
experiment (Figure 2B). We conclude that the Y110E
mutation interferes with the ability of BAK to form
dimers and multimers, and that this results in the
failure to release cytochrome c and activate caspase 3.
In previous studies, we found that neither the BAK
Y110F nor Y110E mutations had any effect on BAK
being able to undergo the N-terminal conformational
change associated with an early step in BAK activation,
indicating that the mutations did not perturb the overall
BAK structure [14]. Since either p53 or BH3 proteins
bring about BAK conformational change by different
routes [16], we next asked whether the BAK mutants
recruited p53 to the mitochondria as efficiently as the
WT protein. The p53 binding site on BAK is located
near the N-terminus of the protein involving residues
E24/E25 [12,16], and p53 recruitment to the mitochon-
dria is dependent on BAK expression [10,18,19]. Follow-
ing DNA damage by UV irradiation, we found that p53
was readily recruited to the mitochondria as was
detected by western blot in mitochondrial extracts of
cells expressing the WT or either of the two mutant
BAK Y110F or Y110E (Figure 3A). As the Bid BH3
sequence interacts with the BAK hydrophobic groove,
we next examined whether Bid was able to Co-IP BAK
Figure 3 Effects of BAK mutations on p53 mitochondrial
translocation and ability to bind Bid. (A) Translocation of p53 into
mitochondria after DNA damage. Mitochondria were isolated from
cells expressing WT BAK, BAK-Y110F or BAK-Y110E mutant proteins
following treatment with ± 10mJ/cm2 UV. p53 was detected by
western blot using the DO1 antibody (upper panel). Expression
levels of the BAK proteins (detected as above) are also shown (lower
panel). (B) Total cell extracts were prepared from HCT116 cells
expressing WT BAK, Y110F or Y110E mutants following treatment
with ± 10mJ/cm2 UV with extraction buffer (20 mM Tris–HCl pH7.4,
135 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol, protease
and phosphatase inhibitor cocktail containing 1% CHAPS).
Immunoprecipitations were performed with anti Bid antibody (Cell
Signalling) and BAK was detected by immunoblotting with rabbit
anti-BAK (Y164, abcam). The input was 5% of the extracts used in
immunoprecipitation reactions. Here and in panel (C) below, the
non-UV treated WT cell extract was used for the IgG control
immunoprecipitation. (C) Mitochondrial-enriched sub-cellular
fractions were prepared from cells expressing WT or BAK mutants ±
UV treatment as outlined in Figure 1. Immunoprecipitations for Bid
and detection of BAK by western blotting were as in (B) above. The
input was 5% of the extracts used in immunoprecipitation reactions.
Figure 2 Cytochrome c release and caspase3 activation in BAK
mutant cells. (A) Cytochrome c release assays were performed
essentially as described [15,16]. Mitochondria were isolated from
HCT116-WT BAK (top panel), HCT1116-Y110F (middle panel) and
HCT116-Y110E (bottom panel) cells and incubated with recombinant
tBid (1 ng/μl, R&D). After incubation at 37°C for 30 min,
mitochondria were separated into pellet and supernatant fractions
by centrifugation. Cytochrome c levels were analysed by western
blotting with anti-cytochrome c antibody (BD Pharmingen) in both
pellet (indicating retention in mitochondria) and supernatant (sup;
released from mitochondria) fractions. In all cytochrome c release
assays, an equal amount of isolated mitochondria not treated with
tBid was used as input. (B) Activation of caspase 3 was analysed by
FACS using an antibody that specifically recognises only cleaved
(therefore active) form of caspase 3 in HCT116 cells expressing WT BAK,
BAK-Y110F or BAK-Y110E mutants treated with ± 10mJ/cm2 UV. Data
are the mean percentage of 3 independent experiments, ±S.E.M.
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pull down BAK protein following UV irradiation from
whole cell extracts of cells expressing either the WT or
Y110F mutant BAK proteins (Figure 3B). Somewhat sur-
prisingly, Bid was able to pull down more BAK from the
Y110E cells when compared to cells expressing either
WT or the Y110F mutant (Figure 3B). To explore fur-
ther the role of a negative charge at Y110 on the recruit-
ment of Bid to BAK, we performed similar IP/western
blot experiments using mitochondrial enriched prepara-
tions. We found that similar levels of Bid were able to
be immunoprecipitated in the three BAK cell lines ex-
pressing either WT, Y110F or Y110E mutants, irrespect-
ive of whether the cells has been treated with UV or not
(Figure 3C). As before, WT or Y110F BAK proteins were
only co-precipitated with Bid following UV damage, andthat a greater amount of the Y110E BAK mutant we
again found was readily pulled down by Co-IP with Bid
following UV treatment (Figure 3C). However, in these
mitochondrial enriched subcellular fractions we were
also now able to detect BAK that had been pulled down
by the Bid antibody even in the absence of UV treat-
ment. Together these findings provides the first evidence
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surface groove may be a factor important in the recruit-
ment of BH3 proteins such as Bid to BAK.
Blockade of the BAK hydrophobic groove by phos-
phorylation of S117, or an S117E mutant, each impair
binding of either BH3 peptides or proteins to BAK. Lo-
cated further along the same helix as S117 but also
facing the hydrophobic BAK surface pocket, we now
identify a role for Y110 in the BAK activation process.
Taken together, our results identify for the first time
a novel and important bi-functional role for post-
translational modifications at Y110. Binding of BH3 pro-
teins to BAK has been reported to occur with high affinity
yet the interaction must be transient [20], as the same
hydrophobic surface interface is required to nucleate BAK
dimerization. We recently reported that phosphorylation
of BAK at S117 blocks access of BH3 sequences of Bid
and BAK to the hydrophobic pocket on BAK. In contrast,
these findings suggest that while the Y110E mutant inter-
feres with the ability to form stable BAK-BH3:BAK-groove
interactions for dimerization, a negative charge at this site
may also be a positive factor that is involved in the recruit-
ment of BH3-containing proteins, such as Bid, to BAK.
This implies that dephosphorylation of S117 must occur
prior to dephosphorylation of Y110 in order to permit Bid
recruitment, however the exact timing of these events and
whether binding of other BH3-containing BCL-2 family
proteins is also affected by this modification remains to be
established.
Findings presented here further underscore the im-
portance of post-translational modifications in regulating
different steps in BAK activation, and may reveal new
avenues to either potentiate or inhibit BAK activity
through modulation of the phosphorylation status of the
protein.
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